Literature DB >> 17531201

Anti-angiogenic peptides identified in thrombospondin type I domains.

Emmanouil D Karagiannis1, Aleksander S Popel.   

Abstract

Thrombospondin 1, the prototypical protein of the thrombospondin protein family, is a potent endogenous inhibitor of angiogenesis. Although the effects of the thrombospondin 1 on neovascularization have been well studied, little is known about the anti-angiogenic potency of other proteins or peptide fragments derived from the proteins in this family. Here we identify a set of 18 novel, anti-angiogenic 17- to 20-amino acid peptides that are derived from proteins containing type I thrombospondin motifs. We have named these peptides adamtsostatin-4, adamtsostatin-16, adamtsostatin-18, cartilostatin-1, cartilostatin-2, fibulostatin-6.2, fibulostatin-6.3, papilostatin-1, papilostatin-2, properdistatin, scospondistatin, semastatin-5A.1, semastatin-5A.2, semastatin-5B, thrombostatin containing-1, thrombostatin contaning-3, thrombostatin contaning-6, and wispostatin-1 to reflect their origin. We further demonstrate that these peptides inhibit the proliferation and migration of human umbilical vein endothelial cells in vitro. The anti-proliferative and anti-migratory properties of the identified peptides may be important in maintaining angiogenic homeostasis in vivo and make these peptides suitable candidates for use as anti-angiogenic pharmaceutical agents in numerous therapeutic applications.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17531201      PMCID: PMC1945092          DOI: 10.1016/j.bbrc.2007.05.041

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  30 in total

Review 1.  Membrane glycoprotein CD36: a review of its roles in adherence, signal transduction, and transfusion medicine.

Authors:  D E Greenwalt; R H Lipsky; C F Ockenhouse; H Ikeda; N N Tandon; G A Jamieson
Journal:  Blood       Date:  1992-09-01       Impact factor: 22.113

2.  Identification of novel beta1 integrin binding sites in the type 1 and type 2 repeats of thrombospondin-1.

Authors:  Maria J Calzada; Douglas S Annis; Bixi Zeng; Cezary Marcinkiewicz; Bernhard Banas; Jack Lawler; Deane F Mosher; David D Roberts
Journal:  J Biol Chem       Date:  2004-08-03       Impact factor: 5.157

Review 3.  Thrombospondin modules and angiogenesis.

Authors:  M Luisa Iruela-Arispe; Alfonso Luque; Nathan Lee
Journal:  Int J Biochem Cell Biol       Date:  2004-06       Impact factor: 5.085

4.  Neuroblastoma angiogenesis is inhibited with a folded synthetic molecule corresponding to the epidermal growth factor-like module of the follistatin domain of SPARC.

Authors:  Alexandre Chlenski; Shuqing Liu; Lisa J Baker; Qiwei Yang; Yufeng Tian; Helen R Salwen; Susan L Cohn
Journal:  Cancer Res       Date:  2004-10-15       Impact factor: 12.701

5.  Identification of novel short peptides derived from the alpha 4, alpha 5, and alpha 6 fibrils of type IV collagen with anti-angiogenic properties.

Authors:  Emmanouil D Karagiannis; Aleksander S Popel
Journal:  Biochem Biophys Res Commun       Date:  2007-01-16       Impact factor: 3.575

6.  Thrombospondin 2 regulates cell proliferation induced by Rac1 redox-dependent signaling.

Authors:  Neuza Lopes; David Gregg; Sanjay Vasudevan; Hamdy Hassanain; Pascal Goldschmidt-Clermont; Hervé Kovacic
Journal:  Mol Cell Biol       Date:  2003-08       Impact factor: 4.272

7.  Cleavage of the matricellular protein SPARC by matrix metalloproteinase 3 produces polypeptides that influence angiogenesis.

Authors:  E Helene Sage; May Reed; Sarah E Funk; Thao Truong; Melissa Steadele; Pauli Puolakkainen; Donald H Maurice; James A Bassuk
Journal:  J Biol Chem       Date:  2003-07-16       Impact factor: 5.157

Review 8.  Role of angiogenesis in tumor growth and metastasis.

Authors:  Judah Folkman
Journal:  Semin Oncol       Date:  2002-12       Impact factor: 4.929

9.  An antiangiogenic urokinase-derived peptide combined with tamoxifen decreases tumor growth and metastasis in a syngeneic model of breast cancer.

Authors:  YongJing Guo; Andrew P Mazar; Jean-Jacques Lebrun; Shafaat A Rabbani
Journal:  Cancer Res       Date:  2002-08-15       Impact factor: 12.701

View more
  14 in total

1.  ADAMTS-2 functions as anti-angiogenic and anti-tumoral molecule independently of its catalytic activity.

Authors:  J Dubail; F Kesteloot; C Deroanne; P Motte; V Lambert; J-M Rakic; C Lapière; B Nusgens; A Colige
Journal:  Cell Mol Life Sci       Date:  2010-06-24       Impact factor: 9.261

2.  Peptides derived from type IV collagen, CXC chemokines, and thrombospondin-1 domain-containing proteins inhibit neovascularization and suppress tumor growth in MDA-MB-231 breast cancer xenografts.

Authors:  Jacob E Koskimaki; Emmanouil D Karagiannis; Elena V Rosca; Farhad Vesuna; Paul T Winnard; Venu Raman; Zaver M Bhujwalla; Aleksander S Popel
Journal:  Neoplasia       Date:  2009-12       Impact factor: 5.715

3.  A systematic methodology for proteome-wide identification of peptides inhibiting the proliferation and migration of endothelial cells.

Authors:  Emmanouil D Karagiannis; Aleksander S Popel
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-09       Impact factor: 11.205

4.  Anti-angiogenic properties of ADAMTS-4 in vitro.

Authors:  Yi-Ping Hsu; Carolyn A Staton; Neil Cross; David J Buttle
Journal:  Int J Exp Pathol       Date:  2012-02       Impact factor: 1.925

5.  Novel peptide-specific quantitative structure-activity relationship (QSAR) analysis applied to collagen IV peptides with antiangiogenic activity.

Authors:  Corban G Rivera; Elena V Rosca; Niranjan B Pandey; Jacob E Koskimaki; Joel S Bader; Aleksander S Popel
Journal:  J Med Chem       Date:  2011-09-13       Impact factor: 7.446

Review 6.  ADAMTS proteases in vascular biology.

Authors:  Juan Carlos Rodríguez-Manzaneque; Rubén Fernández-Rodríguez; Francisco Javier Rodríguez-Baena; M Luisa Iruela-Arispe
Journal:  Matrix Biol       Date:  2015-02-17       Impact factor: 11.583

7.  Angiogenesis-associated crosstalk between collagens, CXC chemokines, and thrombospondin domain-containing proteins.

Authors:  Corban G Rivera; Joel S Bader; Aleksander S Popel
Journal:  Ann Biomed Eng       Date:  2011-05-18       Impact factor: 3.934

Review 8.  The roles of ADAMTS in angiogenesis and cancer.

Authors:  Yi Sun; Jintuan Huang; Zuli Yang
Journal:  Tumour Biol       Date:  2015-04-28

9.  Effects of rosiglitazone on ovarian function and fertility in animals with reduced fertility following fetal and neonatal exposure to nicotine.

Authors:  J J Petrik; H C Gerstein; C E Cesta; L D Kellenberger; N Alfaidy; A C Holloway
Journal:  Endocrine       Date:  2009-08-20       Impact factor: 3.633

10.  Potential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancer.

Authors:  Andrew R Reynolds
Journal:  Dose Response       Date:  2010-04-23       Impact factor: 2.658

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.